Nuclear Medicine and Biology
Volume 36, Issue 2 , Pages 191-197 , February 2009

Expressions of glucose transporter Types 1 and 3 and hexokinase-II in diffuse large B-cell lymphoma and other B-cell non-Hodgkin's lymphomas

  • Hye Kyung Shim

      Affiliations

    • Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Korea
    • ,
  • Won Woo Lee

      Affiliations

    • Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Korea
    • Institute of Radiation Medicine, Medical Research Center, Seoul National University, Korea
    • Corresponding Author InformationCorresponding author. Department of Nuclear Medicine, Seoul National University Bundang Hospital, Gyeonggi-do 463-707, Korea. Tel.: +82 31 787 7672; fax: +82 31 787 4018.
    • ,
  • So Yeon Park

      Affiliations

    • Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Korea
    • ,
  • Haeryoung Kim

      Affiliations

    • Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Korea
    • ,
  • Young So

      Affiliations

    • Department of Nuclear Medicine, Konkuk University School of Medicine, Korea
    • ,
  • Sang Eun Kim

      Affiliations

    • Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Korea
    • Institute of Radiation Medicine, Medical Research Center, Seoul National University, Korea

Received 1 October 2008 ,Revised 14 November 2008 ,Accepted 21 November 2008.

References 

  1. Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio JA, Zhuang H, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003;101:3875–3876
  2. Israel O, Keidar Z, Bar-Shalom R. Positron emission tomography in the evaluation of lymphoma. Semin Nucl Med. 2004;34:166–179
  3. Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med. 2005;46:958–963
  4. Schoder H, Noy A, Gonen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:4643–4651
  5. Tsukamoto N, Kojima M, Hasegawa M, Oriuchi N, Matsushima T, Yokohama A, et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer. 2007;110:652–659
  6. Friedberg JW, Chengazi V. PET scans in the staging of lymphoma: current status. Oncologist. 2003;8:438–447
  7. Smith TA. The rate-limiting step for tumor [18F]fluoro-2-deoxy-d-glucose (FDG) incorporation. Nucl Med Biol. 2001;28:1–4
  8. Wahl RL. Principles of Cancer Imaging with Fluorodeoxyglucose. In:  Wahl RL editors. Principles and practice of positron emission tomography. Philadelphia: Lippincott Williams and Wilkins; 2002;p. 100–110
  9. Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede MH, Wada M, et al. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43:173–180
  10. Lee JD, Yang WI, Park YN, Kim KS, Choi JS, Yun M, et al. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake. J Nucl Med. 2005;46:1753–1759
  11. Zhao S, Kuge Y, Mochizuki T, Takahashi T, Nakada K, Sato M, et al. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med. 2005;46:675–682
  12. Pedersen PL. Warburg, me and Hexokinase 2: multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the “Warburg Effect”, i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr. 2007;39:211–222
  13. Paudyal B, Oriuchi N, Paudyal P, Higuchi T, Nakajima T, Endo K. Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]-2-fluro-2-deoxy-d-glucose positron emission tomography. Cancer Sci. 2008;99:260–266
  14. Hehn ST, Grogan TM, Miller TP. Utility of fine-needle aspiration as a diagnostic technique in lymphoma. J Clin Oncol. 2004;22:3046–3052
  15. Nguyen XC, So Y, Chung JH, Lee WW, Park SY, Kim SE. High correlations between primary tumours and loco-regional metastatic lymph nodes in non-small-cell lung cancer with respect to glucose transporter type 1-mediated 2-deoxy-2-F18-fluoro-d-glucose uptake. Eur J Cancer. 2008;44:692–698
  16. Smith TA. Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci. 2000;57:170–178
  17. Kawai N, Nishiyama Y, Miyake K, Tamiya T, Nagao S. Evaluation of tumor FDG transport and metabolism in primary central nervous system lymphoma using [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) kinetic analysis. Ann Nucl Med. 2005;19:685–690
  18. Nishiyama Y, Yamamoto Y, Monden T, Sasakawa Y, Kawai N, Satoh K, et al. Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma. Eur J Nucl Med Mol Imaging. 2007;34:78–86
  19. Higashi T, Tamaki N, Honda T, Torizuka T, Kimura T, Inokuma T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med. 1997;38:1337–1344
  20. Higashi T, Tamaki N, Torizuka T, Nakamoto Y, Sakahara H, Kimura T, et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med. 1998;39:1727–1735
  21. Higashi K, Ueda Y, Sakurai A, Wang XM, Xu L, Murakami M, et al. Correlation of Glut-1 glucose transporter expression with [18F]FDG uptake in non-small cell lung cancer. Eur J Nucl Med. 2000;27:1778–1785
  22. Brown RS, Goodman TM, Zasadny KR, Greenson JK, Wahl RL. Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol. 2002;29:443–453
  23. Chung JH, Lee WW, Park SY, Choe G, Sung SW, Chung JK, et al. FDG uptake and glucose transporter type 1 expression in lymph nodes of non-small cell lung cancer. Eur J Surg Oncol. 2006;32:989–995
  24. Barros LF, Porras OH, Bittner CX. Why glucose transport in the brain matters for PET. Trends Neurosci. 2005;28:117–119
  25. Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S, et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer. 2003;97:1015–1024
  26. Song YS, Lee WW, Chung JH, Park SY, Kim YK, Kim SE. Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung. Lung Cancer. 2008;61:54–60
  27. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res. 1996;56:1164–1167
  28. Koga H, Matsuo Y, Sasaki M, Nakagawa M, Kaneko K, Hayashi K, et al. Differential FDG accumulation associated with GLUT-1 expression in a patient with lymphoma. Ann Nucl Med. 2003;17:327–331
  29. Mueckler M. Facilitative glucose transporters. Eur J Biochem. 1994;219:713–725
  30. Sorbara LR, Maldarelli F, Chamoun G, Schilling B, Chokekijcahi S, Staudt L, et al. Human immunodeficiency virus type 1 infection of H9 cells induces increased glucose transporter expression. J Virol. 1996;70:7275–7279

☆ This work was supported by the Korea Research Foundation Grant funded by the Korean Government (MOEHRD, Basic Research Promotion Fund) (KRF-2007-331-E00168) and by the Korea Science and Engineering Foundation (KOSEF) Grant funded by the Korean government (MOST) (No. 2008-01386).

PII: S0969-8051(08)00250-3

doi: 10.1016/j.nucmedbio.2008.11.009

Nuclear Medicine and Biology
Volume 36, Issue 2 , Pages 191-197 , February 2009

Article Tools

* Image Usage & Resolution